Enliven Therapeutics, Inc.
NASDAQ•ELVN
CEO: Mr. Samuel S. Kintz M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-03-12
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Contact Information
Market Cap
$2.81B
P/E (TTM)
-29.3
24.5
Dividend Yield
--
52W High
$48.53
52W Low
$14.79
52W Range
Rank51Top 71.3%
3.0
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data